Drug Trial Radar · NCT04047563
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Nov 10, 2019
Primary completion
Feb 10, 2022
Study completion Feb 10, 2022
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of sovateltide (IRL-1620 or PMZ-1620) therapy along with standard supportive care in patients of acute ischemic stroke.
Conditions
- Cerebral Ischemia
- Cerebral Infarction
- Stroke, Acute
Interventions
Normal Saline along with standard treatmentDrug
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
PMZ-1620 (sovateltide) along with standard treatmentDrug
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in National Institute of Health Stroke Scale (NIHSS)Time frame: 90 days
- Change in modified Rankin Scale (mRS)Time frame: 90 days
- Change in Barthel index [BI]Time frame: 90 days
- Change in the proportion of ischemic stroke patients with NIHSS score <6Time frame: 90 days
- Change in the proportion of ischemic stroke patients with mRS score <2Time frame: 90 days
- Change in the proportion of ischemic stroke patients with Barthel index (BI) score >60Time frame: 90 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Radiant Superspeciality Hospital
Amravati, India
Post Graduate Institute of Medical Education and Research
Chandigarh, India
Lalitha Superspecialities Hospital
Guntur, India
Dayanand Medical College & Hospital
Ludhiana, India
Department of Neurology, Christian Medical College and Hospital
Ludhiana, India
Sidhu Hospital Pvt. Ltd.
Ludhiana, India
New Era Hospital & Research Institute
Nagpur, India
Chopda Medicare & Research Centre
Nashik, India
All India Institute of Medical Sciences
New Delhi, India
Indian Spinal Injury Centre
New Delhi, India
Pushpanjali Hospital & Research Centre Pvt. Ltd
Agra, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.